Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Monday, May 29, 2017
 
Recommended for you
3 Things In Biotech You Should Learn Today: May 28, 2017
Seeking Alpha • Zach Hartman
3 Things In Biotech You Should Learn Today: May 27, 2017
Seeking Alpha • Zach Hartman
Middlemen Are Not Passing On All Drug Discounts Intended For Patients
Forbes • Capital Flows, Contributor
Founders Share How They Effectively Transitioned From Employee To Entrepreneur
Forbes • Contributor, Rhonesha Byng
Therapy Focus - Not Quite The Hammer For Sickle Cell Disease
Seeking Alpha • E.P. Vantage
Spark Therapeutics: Upcoming FDA Catalyst
Seeking Alpha • David Zanoni
California Public Employees Union Pensions are Huge Hypocrites on Drug Prices
Red State • Dan Spencer
Epoetin Alfa Biosimilar Clears FDA Hurdle
MedPage Today • Charles Bankhead
Spark Therapeutics: The Next Big Thing In Gene Therapy?
Seeking Alpha • Benjamin Handler
Bone Drug No Help in RA Erosions (CME/CE)
MedPage Today • Nancy Walsh
 
Recommended for You
Cancer, Epidemiology
3 Things In Biotech You Should Learn Today: May 28, 2017
Seeking AlphaZach Hartman
Summary Second-generation kinase inhibition now approved in ALK-positive lung cancer. Protagonist Therapeutics ushers in studies for a novel solution to iron overload. Quest PharmaTech moves the needle in ovarian cancer. Welcome to another edition of "3 Things in Biotech You Should Learn...
Share
Biotechnology, Health Finance
3 Things In Biotech You Should Learn Today: May 27, 2017
Seeking AlphaZach Hartman
Summary Kite Pharma's journey is a priority for the FDA. Pfizer moves biosimilar epoetin to the market. Boehringer Ingelheim delivers another blow to idiopathic pulmonary fibrosis. Welcome to another edition of "3 Things in Biotech You Should Learn Today," a digest designed...
Share
Cancer, Pfizer, Inc.
Middlemen Are Not Passing On All Drug Discounts Intended For Patients
ForbesCapital Flows, Contributor
The Future Of Health Insurance Over 400,000 Americans with cancer suffer from a second disease -- "financial toxicity." The symptoms include missed mortgage and rent payments, raided retirement accounts and decisions about whether to take medicines as prescribed or ration them to...
Share
Entrepreneurship, Pfizer, Inc.
Founders Share How They Effectively Transitioned From Employee To Entrepreneur
ForbesContributor, Rhonesha Byng
Tweet This Value comes from your relationships, your hustle, your ability to read between the lines and think ahead Founders: This Is How You Handle Rejection Back in the day, (not too long ago - shout out to the class of 2011!)...
Share
Fish Oil, Health Finance
Therapy Focus - Not Quite The Hammer For Sickle Cell Disease
Seeking AlphaE.P. Vantage
When it comes to serious diseases with virtually no treatments the US FDA has shown flexibility in approving new therapies, even if these have questionable efficacy. This could play out again when the agency decides on Emmaus' Endari for sickle cell disease...
Share
Health Finance, Pfizer, Inc.
Spark Therapeutics: Upcoming FDA Catalyst
Seeking AlphaDavid Zanoni
Summary Spark Therapeutics’ recently applied for an FDA approval for its blindness-related one-time gene therapy treatment. The treatment has a high accuracy rate. Spark could be a key player in the gene therapy space for the long term. One promising aspect of...
Share
AARP, Abbott Laboratories
California Public Employees Union Pensions are Huge Hypocrites on Drug Prices
Red StateDan Spencer
Two huge California public employee union pension programs are trying to eat their cake and profit from it too. They are helping to make a stink out of drug prices, even as those same drug prices are helping to prop up their...
Share
Cancer, Health Care Industry
Epoetin Alfa Biosimilar Clears FDA Hurdle
MedPage TodayCharles Bankhead
WASHINGTON -- A biosimilar for epoetin alfa (Epogen, Procrit), the big-selling biologic anemia drug, won near-unanimous support for FDA approval for a broad indication for clinical use from an advisory committee. The Oncology Drugs Advisory Committee (ODAC) voted 14-1 to recommend approval...
Share
GlaxoSmithKline plc, Health Finance
Spark Therapeutics: The Next Big Thing In Gene Therapy?
Seeking AlphaBenjamin Handler
Summary Spark Therapeutics has finished its submission to the FDA and seeks approval for a revolutionary gene therapy to treat a vision impairing genetic disease. The fact that this treatment is a one-time injection brings up an ethical pricing dilemma. An approval...
Share
GlaxoSmithKline plc, Health Care Industry
Bone Drug No Help in RA Erosions (CME/CE)
MedPage TodayNancy Walsh
A year of treatment with teriparatide (Forteo) failed to reduce the volume of bone erosions among patients with longstanding rheumatoid arthritis (RA) whose disease was controlled on tumor necrosis factor (TNF) inhibitors, a small randomized trial found. In a cohort of 24...
Share